PACE-CME

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

Molecular mechanisms involved in the beneficial effect of BET inhibition  in experimental renal disease
RestartResume
    10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain
    • Overview

      Marta Ruiz-Ortega sheds light on the new and exciting field of epigenetics, and how BET inhibition might provide an interesting therapeutic target in renal disease. She shares experimental data dat demonstrate the beneficial effects of BET inhibition.

    • Educational information

      • To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
      • To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
      • To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
      • To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
    • Disclosures

      Marta Ruiz-Ortega, PhD , Fundación Jiménez Díaz,Madrid, Spain

    • Funding

      The symposium was supported by an unrestricted educational grant from Resverlogix Corp

      The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

    Facebook Comments

    Register

    We’re glad to see you’re enjoying PACE-CME…
    but how about a more personalized experience?

    Register for free